MedTrace Logo

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

NCT04170309 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 428

Last updated 2023-07-07

No results posted yet for this study

Summary

In this observational study, data from patients treated with the antibiotic ceftobiprole in the past will be collected. The sponsor of the study is Correvio International Sárl, based in Switzerland. Correvio has committed to the health authorities to obtain further information on possible side effects especially in patients suffering from impaired liver or renal function or immune system deficiency and compare these effects to the ones observed in patients without these health problems. Patient data are collected from historic patient charts, patients will not be treated for the purpose of this data collection. All efforts are being made to capture the data of all patients who meet the inclusion criteria and have received at least one dose of ceftobiprole since this drug was first prescribed at the site.

Conditions

  • Renal Insufficiency
  • Hepatic Insufficiency
  • Immunosuppression

Interventions

DRUG

Ceftobiprole medocaril

Participants in whom treatment with Ceftobiprole medocaril has been completed

Sponsors & Collaborators

  • AMS Advanced Medical Services GmbH

    collaborator INDUSTRY

  • APCER Life Sciences

    collaborator UNKNOWN

  • Advanz Pharma

    lead INDUSTRY

Principal Investigators

  • Noëlle Jemmely · ADVANZ PHARMA Switzerland Sàrl

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2023-06-09
Completion
2023-06-09

Countries

  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04170309 on ClinicalTrials.gov